Literature DB >> 10740264

Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures.

F Hesse1, R Wagner.   

Abstract

During recent years, biopharmaceutical products manufactured by processes that use mammalian cell cultures have gained increasing importance. At the same time, a strong awareness of the importance of the safety and quality of such products has also emerged. This has led to improvements in cultivation and production technology, validation procedures and process organization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740264     DOI: 10.1016/s0167-7799(99)01420-1

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  7 in total

1.  Microplates with integrated oxygen sensing for medium optimization in animal cell culture.

Authors:  Rahul Ravi Deshpande; Chistoph Wittmann; Elmar Heinzle
Journal:  Cytotechnology       Date:  2005-06-16       Impact factor: 2.058

2.  Semliki Forest Virus replicon particles production in serum-free medium BHK-21 cell cultures and their use to express different proteins.

Authors:  Sandra Fernanda Suárez-Patiño; Thaissa Consoni Bernardino; Eutimio Gustavo Fernández Núñez; Renato Mancini Astray; Carlos Augusto Pereira; Hugo R Soares; Ana S Coroadinha; Soraia Attie Calil Jorge
Journal:  Cytotechnology       Date:  2019-08-17       Impact factor: 2.058

3.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

4.  A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits.

Authors:  David H Mulama; Lorraine Z Mutsvunguma; Jennifer Totonchy; Peng Ye; Joslyn Foley; Gabriela M Escalante; Esther Rodriguez; Ramina Nabiee; Murali Muniraju; Felix Wussow; Anne K Barasa; Javier Gordon Ogembo
Journal:  Vaccine       Date:  2019-06-11       Impact factor: 3.641

5.  Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Authors:  Sujin Lee; Fu-Shi Quan; Youngman Kwon; Kaori Sakamoto; Sang-Moo Kang; Richard W Compans; Martin L Moore
Journal:  Antiviral Res       Date:  2014-09-18       Impact factor: 5.970

6.  Expression of recombinant human coagulation factor VII by the Lizard Leishmania expression system.

Authors:  Sina Mirzaahmadi; Golnaz Asaadi-Tehrani; Mojgan Bandehpour; Nooshin Davoudi; Leila Tahmasbi; Nahid Hosseinzadeh; Hasan Mirzahoseini; Kazem Parivar; Bahram Kazemi
Journal:  J Biomed Biotechnol       Date:  2011-09-08

7.  A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.

Authors:  Javier Gordon Ogembo; Matthew R Muraswki; Lori W McGinnes; Agapi Parcharidou; Rujapak Sutiwisesak; Timelia Tison; Juan Avendano; Deep Agnani; Robert W Finberg; Trudy G Morrison; Joyce D Fingeroth
Journal:  J Transl Med       Date:  2015-02-06       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.